Biocon, as part of its decision to expand its research base in India, has acquired some assets from Pfizer Healthcare to set up its second R&D plant in the country.
Biocon Biologics, a subsidiary of the Bengaluru-based company, has acquired the assets for an undisclosed amount to set up a 60,000 square feet state-of-the-art R&D facility in Chennai.
Christiane Hamacher, CEO, Biocon Biologics, said, “The high-end integrated R&D facility in Chennai will enable Biocon Biologics to expand its R&D capability and accelerate its journey towards meeting its strategic long-term goal of addressing the needs of millions of patients worldwide.”
It is expected the centre will be operational in a few months. At present, Biocon has a 200,000 square feet R&D centre at Bengaluru which has a product pipeline of 28 molecules, including 11 with Mylan, few with Sandoz and rest on its own.
Image Credit : trends.gulte.com